Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients

Inclusion Criteria:

• Male or female, Age ≥ 18 years

• Have a histological or cytological confirmed solid tumor malignancy

• Patient scheduled to receive their first course of anthracycline cyclophosphamide (AC)based chemotherapy regimen or Moderately Emetogenic Chemotherapy for the treatment ofsolid malignant tumor

• Patient scheduled to receive CINV prevention with AKYNZEO® or Standard of Careaccording to the summary of product characteristics based on the judgement of theirinvestigator's

• Naïve of CT

• ECOG performance up to 2

• Able to read, understand and follow the study procedures

• Patient with Health insurance

Exclusion Criteria:

• Pregnancy and breastfeeding women;

• Hypersensitivity to active substances, excipients or other ingredients of Akynzeo® orEmend®;

• Protected patients: majors under guardianship, tutorship or other legal protection,deprived of liberty by judicial or administrative decision